Navigation Links
AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Date:4/1/2008

n new cases per year of cutaneous leishmaniasis and an estimated prevalence of 12 million people already infected.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at http://www.paladinlabs.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Both AEterna Zentaris and Paladin Labs (collectively, the "Companies") consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended Dec
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 ... tracking to reporting eLearning solution using Tin Can ... and dashboard tool. CLD is a leading developer ... and medical device companies worldwide. , Tin ... standard that helps learners and trainers more accurately ...
(Date:5/21/2013)... 21, 2013 Alpha Source, Inc., ... will be exhibiting for the 13th consecutive year ... Instrumentation (AAMI) 2013 Conference and Expo. The conference ... and manufacture healthcare technologies. This year’s event will ... California. , The three-day event draws over ...
(Date:5/21/2013)... Clinverse, Inc. , a ... trials, announced today it has formed a strategic ... ClinPay® FLS eClinical commerce platform aggregates data collected ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship product, ... reporting transfer of value at investigator meetings or ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3
(Date:5/21/2013)... A new analysis shows that the nation,s land ... enough algae to produce up to 25 billion gallons ... one-twelfth of the country,s yearly needs. , The findings ... that would be needed to grow significant amounts of ... were published in the May 7 issue of ...
(Date:5/21/2013)... class of pharmaceuticals can both prevent and treat Alzheimer,s ... "TSPO ligands," are currently used for certain types of ... ligand in young adult mice when pathology was at ... was quite severe," said lead researcher Christian Pike of ... measures of pathology and improved behavior at both ages." ...
(Date:5/21/2013)... become most deadly when they metastasize and spread tumors ... it becomes very difficult for doctors to locate and ... at the University of Missouri have found a way ... wherever they may be in the body. Michael Lewis, ... of Veterinary Medicine, says being able to target secondary ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... With more than 1.7 million people sustaining a traumatic ... to limit inflammation and subsequent damage is critical. Approximately ... leaving 85,000 with long-term disabilities and taking the lives ... live with disabilities caused by traumatic brain injuries, often ...
... (New York, NY, April 22, 2012) Researchers at ... pathway that controls the retention and release of the ... normal and abnormal neurologic development and could eventually lead ... findings, from a collaborative effort of the laboratories of ...
... in Science shows that mountain plants across the ... raised species numbers on mountain tops, when colonizers from lower ... also shows that upward shifts can lead to a reduction ... of 66 mountain summits distributed between the north of Europe ...
Cached Biology News:Estrogen hormone reveals protective ability after traumatic brain injury 2'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3Accelerating climate change exerts strong pressure on Europe's mountain flora 2
DTT 50 l...
...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: